BiotechTube
EXOSOMICS

EXOSOMICS

Siena, Italy· Est.
exosomics.eu
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15.2M

Overview

Exosomics is a private, integrated biotechnology company with a core focus on exosome-based diagnostics for early cancer detection. Founded in 2011, it has expanded its business model to include three distinct arms: Rivela Diagnostics for MCED tests, HansaBioMed Life Sciences for EV research tools and services, and a joint venture, LongEVity Bioscience, for beauty applications. The company is positioned at the intersection of the rapidly growing liquid biopsy and EV markets, aiming to translate vesicle biology into clinical and commercial products.

Oncology

Technology Platform

Proprietary platform for the isolation, purification, and molecular analysis of tumor-derived extracellular vesicles (exosomes) from blood for use as liquid biopsy biomarkers.

Funding History

2
Total raised:$15.2M
Series A$12M
Seed$3.2M

Opportunities

The global push for liquid biopsy-based multi-cancer early detection represents a multi-billion dollar market opportunity.
The company's dual revenue stream from tools (HansaBioMed) and cosmetics (LongEVity) provides financial stability and de-risks the long-term diagnostic development.

Risk Factors

High technical and clinical validation risk for the MCED test in a fiercely competitive landscape.
Regulatory pathways for novel MCED assays are complex and evolving.
As a private European company, access to large-scale funding for pivotal trials may be challenging.

Competitive Landscape

Exosomics competes in the crowded liquid biopsy space against large, well-capitalized public companies like Grail (Illumina), Exact Sciences, and Freenome in MCED, and numerous others in EV research tools. Its differentiation hinges on its specific exosome expertise and integrated business model.

More companies in Diagnostics & Precision Medicine →More companies in Italy →